Eli Lilly’s blockbuster weight loss and diabetes drugs are no longer in shortage, according to the FDA’s database that tracks drugs in limited supply.
The agency’s shortage tracker for Mounjaro and Zepbound listed the drugs as “available” in all dosages as of Friday afternoon. Until Friday, at least four dosages of Mounjaro and Zepbound had been listed as in shortage in the US. Lilly had been struggling to produce enough of the medicines because of huge demand, particularly for anti-obesity uses.
Both drugs are based on the ingredient tirzepatide. Wegovy, Novo Nordisk’s competing weight loss drug, remains in shortage, according to the FDA’s page.
“The FDA continues to actively monitor drug availability and work with the company to confirm the supply is stable and help ensure patient access to safe, effective drugs,” the agency said in an emailed statement.
Lilly didn’t immediately respond to requests for comment.
Editor’s note: This story has been updated with a statement from the FDA.
